GSK761

• CAT Number: I041417
• Molecular Formula: C40H46N4O4
• Molecular Weight: 646.82
• Purity: ≥95%
• Synonyms: 1-methyl-N-[3-[2-[(2-methylpropan-2-yl)oxy]ethyl]phenyl]-2-[4-[[3-[2-[(2-methylpropan-2-yl)oxy]ethyl]phenyl]carbamoyl]phenyl]benzimidazole-5-carboxamide
• InChI: InChI=1S/C40H46N4O4/c1-39(2,3)47-22-20-27-10-8-12-32(24-27)41-37(45)30-16-14-29(15-17-30)36-43-34-26-31(18-19-35(34)44(36)7)38(46)42-33-13-9-11-28(25-33)21-23-48-40(4,5)6/h8-19,24-26H,20-23H2,1-7H3,(H,41,45)(H,42,46)
• InChIKey: DAHVZGAYZACXOD-UHFFFAOYSA-N
• SMILES: CC(C)(C)OCCC1=CC(=CC=C1)NC(=O)C2=CC=C(C=C2)C3=NC4=C(N3C)C=CC(=C4)C(=O)NC5=CC=CC(=C5)CCOC(C)(C)C

GSK761（Cat No.:I041417）is a selective, small-molecule inhibitor targeting the protein kinase TBK1 (TANK-binding kinase 1), which plays a pivotal role in regulating immune responses and inflammatory pathways. By inhibiting TBK1, GSK761 shows promise in treating autoimmune and inflammatory diseases, as well as certain neurodegenerative conditions, such as ALS (amyotrophic lateral sclerosis) and frontotemporal dementia. In preclinical studies, GSK761 has demonstrated the ability to reduce inflammatory cytokine production and modulate immune cell activity. Ongoing research is focused on evaluating its safety and efficacy for various therapeutic indications.